Status:
UNKNOWN
CARotid plaqUe StabilizatiOn and Regression With Evolocumab.
Lead Sponsor:
Azienda Ospedaliera Ordine Mauriziano di Torino
Conditions:
Carotid Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque morphological stabilization and regression as compared to traditional lipid lowering therapy (LLT). Primar...
Detailed Description
Optimal lipid-lowering therapy (LLT) is a mainstay for the therapeutic management of atherosclerotic vascular disease. Cardiac and cerebrovascular adverse events and progression of atherosclerosis are...
Eligibility Criteria
Inclusion
- asymptomatic patients with uni- or bilateral carotid artery stenosis ≥50% and LDL-C values ≥100 mg/dL despite ongoing lipid lowering therapy
Exclusion
- age \<18 or ≥81 years old
- known intolerance to evolocumab
- ongoing or previous treatment with PCSK9i
- prior stroke or transient ischemic attack
- total carotid occlusion
- major active infection or major hematologic, renal, hepatic, or endocrine dysfunction
- malignancy with life expectancy below 24 months
- failure to sign informed consent
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04730973
Start Date
March 1 2021
End Date
March 31 2022
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Ordine Mauriziano di Torino
Turin, Piedmont, Italy, 10134